PMID- 30277099
OWN - NLM
STAT- MEDLINE
DCOM- 20200622
LR  - 20231112
IS  - 1029-2403 (Electronic)
IS  - 1042-8194 (Print)
IS  - 1026-8022 (Linking)
VI  - 60
IP  - 4
DP  - 2019 Apr
TI  - Adverse events, resource use, and economic burden associated with mantle cell 
      lymphoma: a real-world assessment of privately insured patients in the United 
      States.
PG  - 955-963
LID - 10.1080/10428194.2018.1509320 [doi]
AB  - In view of recent therapeutic advances in mantle cell lymphoma (MCL), the aim of 
      this retrospective cohort analysis was to assess treatment patterns, adverse 
      events (AEs), resource utilization, and health care costs in patients with MCL in 
      a US-based commercial claims database. A total of 783 patients with MCL (median 
      age = 65 years) were selected. Among patients receiving systemic therapy 
      (n = 457), the most common treatment regimens were bendamustine/rituximab (BR) 
      (41.1%), rituximab/cyclophosphamide/doxorubicin/vincristine (RCHOP) (26.7%), 
      rituximab monotherapy (20.4%), and ibrutinib monotherapy (14.2%). Mean monthly 
      costs during treatments with BR, RCHOP, rituximab, and ibrutinib were $12,958, 
      $24,719, $13,153, and $21,690, respectively. Mean monthly cost during follow-up 
      was $13,650 among patients with >/=6 AEs versus $5131 among those without AEs. The 
      costs of MCL varied considerably by treatment regimen and care setting. The 
      overall economic burden of managing patients with MCL can be substantially 
      affected by costs associated with managing AEs occurring during treatment.
FAU - Goyal, Ravi K
AU  - Goyal RK
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Nagar, Saurabh P
AU  - Nagar SP
AD  - a RTI Health Solutions , Research Triangle Park , NC , USA.
FAU - Kabadi, Shaum M
AU  - Kabadi SM
AD  - b AstraZeneca , Gaithersburg , MD , USA.
FAU - Kaye, James A
AU  - Kaye JA
AD  - c RTI Health Solutions , Waltham , MA , USA.
FAU - Seal, Brian
AU  - Seal B
AD  - b AstraZeneca , Gaithersburg , MD , USA.
FAU - Mato, Anthony R
AU  - Mato AR
AD  - d Department of Medicine, Division of Hematological Malignancies , Memorial Sloan 
      Kettering Cancer Center , New York , NY , USA.
LA  - eng
GR  - P30 CA008748/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20181002
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
MH  - Comorbidity
MH  - *Cost of Illness
MH  - Female
MH  - *Health Resources
MH  - Humans
MH  - *Insurance, Health
MH  - Lymphoma, Mantle-Cell/diagnosis/*epidemiology/therapy
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'
MH  - Proportional Hazards Models
MH  - Public Health Surveillance
MH  - Risk Factors
MH  - United States/epidemiology
MH  - Young Adult
PMC - PMC7564890
MID - NIHMS1624123
OTO - NOTNLM
OT  - MCL
OT  - Mantle cell lymphoma
OT  - adverse events
OT  - costs
OT  - economic burden
OT  - treatment patterns
COIS- Declaration of interest: Ravi K. Goyal, Saurabh P. Nagar, and James A. Kaye are 
      full-time employees of RTI Health Solutions, which received funding from 
      AstraZeneca to conduct this research. RTI Health Solutions is a business unit of 
      Research Triangle Institute, which is an independent, nonprofit, research 
      organization that does work for government agencies and private companies. Shaum 
      Kabadi and Brian Seal are full-time employees of AstraZeneca, the funding 
      organization. Anthony Mato has received research funding and/or has consulting 
      relationship with the following organizations: AbbVie, Acerta, AstraZeneca, 
      Celgene, DTRM, Gilead Sciences, Janssen, Kite, Pharmacyclics, Portola, Regeneron, 
      and TG Therapeutics.
EDAT- 2018/10/03 06:00
MHDA- 2020/06/23 06:00
PMCR- 2020/10/16
CRDT- 2018/10/03 06:00
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2020/06/23 06:00 [medline]
PHST- 2018/10/03 06:00 [entrez]
PHST- 2020/10/16 00:00 [pmc-release]
AID - 10.1080/10428194.2018.1509320 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2019 Apr;60(4):955-963. doi: 10.1080/10428194.2018.1509320. Epub 
      2018 Oct 2.